Arrowhead granted breakthrough therapy designation for plozasiran by FDA

Arrowhead announced that the FDA has granted breakthrough therapy designation to investigational plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome, or FCS, a severe and rare genetic disease characterized by extremely high triglyceride levels which can cause acute and potentially fatal pancreatitis. There are currently no approved treatments in the U.S. for FCS.